Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

Rhea-AI Summary

Design Therapeutics, a clinical-stage biotechnology company focused on serious genetic diseases, announced that CEO João Siffert and COO Sean Jeffries will participate in a fireside chat at the 2022 Wedbush PacGrow Virtual Healthcare Conference on August 10, 2022, at 10:20 a.m. ET. A live webcast will be accessible on the company's investor website, with an archive available for 30 days post-event.

Design's GeneTAC™ platform aims to develop therapies addressing genetic disorders like Friedreich ataxia and myotonic dystrophy type-1, targeting disease-causing genes.

CARLSBAD, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that João Siffert, M.D., president and chief executive officer, and Sean Jeffries, Ph.D., chief operating officer, will participate in a fireside chat during the 2022 Wedbush PacGrow Virtual Healthcare Conference on Wednesday, August 10, 2022, at 10:20 a.m. ET.

A live webcast will be available in the investor section of the company's website at www.designtx.com. The webcast will be archived for 30 days following the presentation.

About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. Design’s lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions. For more information, please visit designtx.com.

Contact:
Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

FAQ

When will Design Therapeutics present at the Wedbush PacGrow Virtual Healthcare Conference?

Design Therapeutics will present on August 10, 2022, at 10:20 a.m. ET.

How can investors access the Design Therapeutics webcast?

Investors can access the webcast in the investor section of the Design Therapeutics website, available live and archived for 30 days.

What is the focus of Design Therapeutics' GeneTAC™ platform?

The GeneTAC™ platform focuses on developing therapies to address serious genetic diseases by targeting disease-causing genes.

What genetic disorders are targeted by Design Therapeutics?

Design Therapeutics targets disorders such as Friedreich ataxia and myotonic dystrophy type-1.

Who are the key executives participating in the fireside chat?

João Siffert, CEO, and Sean Jeffries, COO, will participate in the fireside chat.